COCH
Envoy Medical, Inc.
There isn't enough reported data to score COCH yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
COCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Strong |
COCH's balance sheet is currently strong, and its revenue is stable, but its profitability is weak. There isn't enough data to rate its cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
COCH PE Valuation
COCH has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
COCH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect COCH's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
COCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.70 | +$10.20 |
| Q2 2026 | -$7.70 | +$7.40 |
| Q1 2026 | -$10.20 | +$4.40 |
| Q4 2025 | -$12.30 | +$2.60 |
COCH is still losing money, but far less than before: $4.70 per share over the past year, against $15.10 at its worst in mid-2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over COCH on earnings quality, reporting a profit while its opponent remains loss making.
COCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $66K | +57% |
| Q2 2026 | $51K | -35% |
| Q1 2026 | $39K | -15% |
| Q4 2025 | $75K | +79% |
| Q3 2025 | $42K | -25% |
| Q2 2025 | $78K | +15% |
| Q1 2025 | $46K | -22% |
| Q4 2024 | $42K | -56% |
COCH's revenue is recovering but still below its 2023 peak: $66,000 last quarter, up 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8389% | +5201 points |
| Q2 2026 | -10920% | -4420 points |
| Q1 2026 | -15279% | -4177 points |
| Q4 2025 | -8513% | +2258 points |
| Q3 2025 | -13590% | -4708 points |
| Q2 2025 | -6500% | +647 points |
| Q1 2025 | -11102% | -2801 points |
| Q4 2024 | -10771% | -3682 points |
COCH's operating margin was −8389% last quarter, up 5201 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over COCH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over COCH on profitability, with a higher operating margin.
COCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.1M | -$726K |
| Q4 2025 | -$5.9M | -$2M |
| Q3 2025 | -$4.3M | -$367K |
| Q4 2024 | -$3.9M | +$7.9M |
COCH has burned cash in almost every quarter: −$20M over the past year, against −$23M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
COCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +30.6K shares |
| 1 year | +378% | +8.2M shares |
| 3 years | +96% | +5.1M shares |
COCH has 10M diluted shares, up 378% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over COCH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
COCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -0.0x | Net Cash |
| Q3 2021 | -0.1x | Net Cash |
COCH has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
COCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.6 | Neutral |
| Stochastic | 62.7 | Neutral |
COCH's weekly RSI is 49 (neutral) and its Stochastic is 63 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
COCH PE vs Healthcare Sector
| Metric | COCH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
COCH has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
COCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.72 | 1.3% above |
| 20 week MA | $6.96 | 2.2% below |
| 50 week MA | $6.90 | 1.3% below |
| 100 week MA | $10.1 | 33% below |
| 200 week MA | $32.4 | 79% below |
COCH has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 79% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over COCH on trend strength, trading above more of its moving averages.
COCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $97.5 | $97.4 | -0.1% |
| 2022 | $97.4 | $99.7 | +2.4% |
| 2023 | $99.7 | $18.1 | -82% |
| 2024 | $18.1 | $16.0 | -12% |
| 2025 | $16.0 | $7.30 | -54% |
| 2026 YTD | $7.30 | $6.81 | -6.7% |
COCH has finished three years in a row lower, and it's down 6.7% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over COCH on returns for 2026, with the stronger performance.